Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating metastatic colorectal cancer mCRC patients who have a specific genetic change called the BRAFV600E mutation. This rare subtype of mCRC often shows poor response to current treatments and has a generally poor outlook. The study aims to collect detailed clinical data and biological samples to better understand this condition, including how patients respond to treatments and what factors predict their survival. It focuses on real-world treatment outcomes and biological markers that might influence therapy choices and resistance. Participants will provide blood samples at multiple times during their treatment, including before and during the first three treatment cycles, at 3 and 6 months after starting each treatment line, and when disease progression occurs following certain therapies. The study gathers up to 390 mL of blood per participant over time to analyze circulating tumor DNA and immune environment factors. This observational approach will help researchers identify biomarkers related to treatment response and disease progression. During the study, participants clinical progress and survival will be tracked for up to five years. Researchers will review overall survival from diagnosis to death and assess how prognostic markers relate to progression-free survival and response to treatments. The study involves collecting tumor tissue samples and blood tests, along with routine follow-up visits. All data collected will contribute to understanding BRAFV600E mCRC and improving future treatment strategies.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating mechanical ventilation strategies and the timing of muscle relaxation in patients with moderate to severe Acute Respiratory Distress Syndrome ARDS. The study aims to test personalized approaches for setting Positive End-Expiratory Pressure PEEP based on lung recruitability and whether early use of neuromuscular blocking agents NMBAs during prone positioning improves survival compared to rescue use. This trial addresses the lack of specific treatments for ARDS and focuses on improving survival by optimizing ventilation methods. Participants will be assigned to different ventilation strategies routine care with minimal lung distension using low tidal volume and conservative PEEP, routine care with maximal lung recruitment adjusting tidal volume and PEEP to maintain safe plateau pressures, or a personalized PEEP strategy based on a PEEP responsiveness test. Additionally, the study compares early systematic use of NMBAs during prone positioning to rescue use. Two randomizations occur first for ventilation strategy and second for NMBA timing. During the study, participants will undergo mechanical ventilation with assigned strategies, and researchers will monitor oxygenation, respiratory parameters, organ function scores, and mortality over time. Assessments include arterial blood gases, tidal volumes, respiratory rates, and organ failure evaluations at multiple time points up to one year. The primary outcome is 28-day all-cause mortality. Safety and long-term outcomes such as disability, cognitive function, quality of life, and return to work status will also be evaluated throughout the follow-up period.
Actively Recruiting
Researchers are studying patients with community-acquired pneumonia who need oxygen therapy due to acute respiratory distress and low blood oxygen levels. This research aims to see if placing patients in a prone position lying face down while they receive nasal high flow oxygen can reduce the need for intubation and improve outcomes. The study particularly excludes patients with COVID-19 and focuses on non-COVID pneumonia cases. Participants will be randomly assigned to one of two groups. One group will be encouraged and assisted to lie in the prone position for at least 8 hours per day in multiple sessions, aiming for up to 16 hours if tolerated. The other group will receive usual care with nasal high flow oxygen therapy but no prone positioning. Both groups will have oxygen levels monitored and care adjusted to maintain target oxygen saturation. During the study, patients will be observed for intubation rates within 28 days, comfort levels during prone positioning, oxygenation changes, time to escalation of breathing support, and overall outcomes including mortality up to 90 days. Safety measures like skin and infection monitoring will also be recorded. Quality of life will be assessed at 90 days and 5 years, with nursing workload tracked within the first day after randomization.
Actively Recruiting
Atrial fibrillation AF is a common heart rhythm disorder linked to a significant number of strokes, especially in people over 65. This research aims to explore the genetic causes and blood clotting processes related to AF and stroke by creating a biological database. Understanding these genetic factors may help identify new targets for treatments. Participants are grouped based on their AF and stroke history, age, and specific medical procedures. Blood samples are collected to obtain DNA and plasma for genetic studies. The study includes patients with AF with or without stroke, those undergoing certain heart procedures, people over 80 without AF, and individuals with early stroke or transient ischemic attack but no AF. During the study, blood samples are collected and stored for quality analysis up to seven years. Clinical data collection accompanies the biological sampling. Researchers will evaluate the quality and preservation of these samples to support genetic research. Participation involves providing blood samples and medical history information, with ongoing monitoring of sample integrity.
Actively Recruiting
This research aims to reduce extubation failure in critically ill patients with acute brain injuries who have impaired consciousness. These patients often require mechanical ventilation with tracheal intubation, and after their acute neurological condition is treated, doctors need to carefully wean them off ventilators to avoid complications like pneumonia. Current guidelines for ventilator weaning do not include brain-injured patients with impaired consciousness, so this study evaluates a simple clinical score to help decide when to safely remove the breathing tube. Participants will be assigned by random clusters of intensive care units to receive either usual care or care guided by the extubation readiness clinical score. After a successful spontaneous breathing trial, clinicians in the intervention group will use the score based on swallowing, gag reflex, cough, and consciousness level to decide on extubation. If the score is above 9, extubation should proceed. Those in the usual care group will follow standard ICU ventilator weaning protocols. The study uses a stepped wedge cluster randomized design. During the study, patients are assessed daily for readiness to breathe without the ventilator. Researchers will monitor extubation failure from the time of extubation up to five days later. They will also track other outcomes such as time to extubation, duration of mechanical ventilation, reintubation rates, pneumonia occurrence, hospital stay length, and neurological outcomes up to 90 days. This thorough evaluation helps understand how the score may improve the timing and success of extubation in this vulnerable group.
Actively Recruiting
Researchers are evaluating a standardized process that combines expert review and advanced software to improve treatment planning for patients undergoing re-irradiation with curative intent. This study aims to determine how often this approach changes treatment plans by using a group of radiotherapists and physicists to validate re-irradiation indications and dose accumulations. The study addresses challenges in managing dose limits to organs at risk during repeat radiation treatments, aiming to reduce treatment inequalities across centers. The intervention involves a multidisciplinary and multicenter validation process where technical data from previous and planned irradiations are reviewed using deformable fusion software called MiM. This software sums doses in Equivalent Dose 2 Grays EQD2 to evaluate cumulative radiation exposure. Patients undergo initial opinion assessment, followed by collective expert reviews of imaging, dose plans, and dose summations in several steps. If re-irradiation is validated, patients proceed with treatment according to the validated plan. Participants are followed for up to two years after re-irradiation to monitor treatment tolerance and effectiveness through standard practice visits approximately every three months. Outcomes measured include the rate of treatment plan changes due to the intervention, local control rates at multiple time points up to 24 months, safety, and impacts on clinical practices. Dose summation timing and treatment adherence are also evaluated. The study enrollment is for adults aged 18 years and older who meet specific clinical criteria for curative re-irradiation.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
Researchers are investigating the use of bone tomoscintigraphy to diagnose cervical pseudarthrosis, a complication that can occur after cervical spine surgery. This condition can cause pain and instability, and its diagnosis is challenging due to nonspecific symptoms and limitations of current imaging methods. The study aims to evaluate the diagnostic value of bone scintigraphy compared to CT scans, which are currently considered the standard but lack functional information about bone healing. Participants will undergo a bone scintigraphy exam in addition to the usual CT scans performed in current practice. This imaging technique combines functional and anatomical data to potentially improve the accuracy of diagnosing cervical pseudarthrosis. The study will compare the sensitivity, specificity, and predictive value of bone scintigraphy and CT scans over a 12-month period. During the study, participants will have clinical scores assessed and imaging tests including bone scintigraphy and CT scans. Researchers will monitor how well bone scintigraphy detects pseudarthrosis and predicts bone consolidation at one year after surgery. The study will last up to 12 months, with assessments focusing on imaging and clinical evaluation to understand the effectiveness of bone scintigraphy in this diagnostic role.
Actively Recruiting
Researchers are conducting a multicenter, phase 3, open-label study to evaluate treatments for patients with newly diagnosed Multiple Myeloma who are eligible for autologous stem cell transplantation ASCT. The study compares the effects of an experimental combination of elranatamab and lenalidomide against the current standard of care, including chemotherapy, ASCT, and maintenance therapies. The purpose is to assess if these new treatment approaches improve outcomes such as minimal residual disease MRD negativity and progression-free survival. Participants will first undergo induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone. Then, they will be randomly assigned to one of two consolidation therapies either standard treatment with high-dose chemotherapy and ASCT followed by D-VRd consolidation, or an experimental consolidation with elranatamab and lenalidomide. After consolidation, patients are re-randomized into maintenance therapy groups receiving either daratumumab plus lenalidomide or elranatamab monotherapy for approximately two years, with treatment adjustments based on MRD status. Throughout the study, participants will have scheduled visits for treatment administration, monitoring, and various assessments including blood tests, imaging, and quality of life questionnaires. Researchers will measure key outcomes such as MRD negativity rates, progression-free survival, overall survival, safety, and tolerability over several years. The study also tracks health-related quality of life and adverse events during induction, consolidation, and maintenance phases, with follow-up extending up to 11 years.
1-10 of 19
1